Conclusions
This case reports a patient with stage IV lung adenocarcinoma treated with a combination of an antiangiogenic inhibitor and an immune checkpoint inhibitor who switched from a combination of camrelizumab and endonuclease to a combination of camrelizumab and bevacizumab with a sustained benefit over 18 months, suggesting that combination immunotherapy may be a treatment option for patients with KRAS mutations in advanced non-small cell lung cancer. Second, the combination of anti-angiogenesis inhibitors and immunotherapy may improve efficacy and with good persistence. Despite encouraging results from studies evaluating the safety and efficacy of this combination therapy, there is currently no head-to-head trial evidence comparing the therapeutic efficacy of ICIs with other therapies such as angiogenesis inhibitors. There is also a need to advance effective immunosurveillance techniques that are closely linked to clinical endpoints. Significant affinities may help to identify favorable immune biomarkers that can then be validated in larger patient cohorts.